Chugai Pharmaceutical

Basic Information

Stock Code: 4519
Industry: Pharmaceuticals
Category Detail: Biotechnology & Pharmaceuticals
Prefecture: Tokyo
Establishment Year: March 1943
Listing Year: March 1956
Official Website: https://www.chugai-pharm.co.jp/
TSE Information: TSE Information
Yahoo! Finance: Yahoo! Finance
Other Companies: Kyowa Kirin, Takeda, Astellas Pharma, Shionogi, Eisai, Ono Pharmaceutical, Hisamitsu Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka HD

Overview

Chugai Pharmaceutical is a major pharmaceutical manufacturer founded in 1943 and headquartered in Tokyo. It boasts advanced biopharmaceutical development capabilities under the Swiss Roche Group umbrella, particularly centered on oncology.

Current Situation

In the fiscal year ended December 2023, Chugai Pharmaceutical achieved consolidated net sales of 1.1113 trillion yen and operating profit of approximately 439.1 billion yen, maintaining high profitability. It primarily develops, manufactures, and sells cutting-edge pharmaceuticals such as anticancer agents and molecular targeted drugs, demonstrating a significant presence not only in Japan but also in global markets. As part of the Roche Group, it maintains a global R&D framework and is developing a diverse pipeline of new biopharmaceuticals. Research institutes and factories are located at multiple sites across Japan, with ongoing technological investments for sustainable growth. In recent years, it has specialized in prescription pharmaceuticals, transferring its over-the-counter drug business to other companies. Backed by a solid financial foundation and a rich product lineup, it aims to introduce new drug discovery technologies and accelerate international expansion toward the late 2020s. From 2024 onward, it is actively investing in R&D while strengthening sustainability and social responsibility initiatives.

Trivia

Interesting Facts

Founded in 1925, one of Japan's established pharmaceutical companies
Maintains independence while in strategic alliance with Roche
Japan's leading oncology development pipeline
Distinctive diagnostic drug business utilizing DNA technology
Over-the-counter brands like Balsan already transferred
Multiple research institutes and factories deployed domestically
World-first launch of antibody drug for Castleman disease treatment
Proprietary brand logo inspired by benzene ring and ampoule
Focus on promoting innovation culture in pharmaceutical industry
History of TV commercials on TBS, Nippon TV, and various media
High social recognition as a top pharmaceutical brand
Pursuing unique strategies amid overseas competition
Possesses massive patent portfolio for new drug development
Focus on sales expansion in global markets
Large-scale enterprise with over 7,600 consolidated employees

Hidden Connections

Valuable company maintaining uniqueness with Tokyo Stock Exchange listing despite being under Roche Group
Deep product licensing and research partnerships with many domestic competitors
Leveraging heritage from integration with former Japan Roche's reagent division for molecular diagnostics
Transferred former OTC brands to Lion and Reck to specialize business
Founder's Ueno family deeply involved in management, preserving history
Castleman disease drug Actemra co-developed with Osaka University
Background of boosting recognition as sponsor of many domestic dramas
Strength in DNA-based diagnostics through acquisition of Gen-Probe

Future Outlook

Growth Drivers

Expanding demand from global increase in cancer patients
Enhanced competitiveness through utilization of Roche Group's international resources
Market growth promotion for molecular targeted and immunotherapy drugs
Sophistication and diversification of advanced medical needs domestically and internationally
Accelerated R&D efficiency via digital technologies
Increased demand for chronic disease treatments with aging population
Overseas sales expansion strategy through global rollout
Elevated social evaluation through sustainability and ESG management
Entry into new disease areas and pipeline expansion
Sales and marketing innovation utilizing digitalization
Growth expectations in advanced medical devices and diagnostics business
対応 to international regulatory compliance and safety enhancements

Strategic Goals

Achieve 2 trillion yen in global pharmaceutical market sales
Sustainable manufacturing and 30% reduction in environmental impact
Complete digital transformation
Stabilize new drug approvals at 5 or more per year
Expand female executive ratio to over 30%
Expand social contributions through improved medical access
Maintain top-class ESG ratings domestically and internationally
Provide innovative medicine across diverse disease areas
Increase R&D expense ratio to over 15% of total sales
Build data integration utilization framework across the group

Business Segments

R&D Support

Overview

Provides advanced research reagents and technical support to accelerate pharmaceutical development.

Competitiveness

Exclusive technologies and resources through collaboration with Roche Group

Customers

Universities and research institutions
Biotech ventures
Pharmaceutical companies
Public research institutions

Products

Research reagents
Molecular diagnostic technology
Biologics
Pipeline sharing

Pharmaceutical Manufacturing Outsourcing

Overview

Offers high-quality contract manufacturing services to support customer production efficiency.

Competitiveness

GMP-compliant manufacturing facilities and technical expertise

Customers

Domestic and international pharmaceutical manufacturers
Generic drug companies
Biopharma companies

Products

Biologic API manufacturing
Pharmaceutical intermediate manufacturing
Quality control and assurance services

Medical Devices and Diagnostic Equipment

Overview

Provides and supports diagnostic-related products essential for medical settings.

Competitiveness

Provision of latest molecular diagnostic technologies

Customers

Hospitals
Clinics
Testing specialized institutions

Products

Diagnostic reagents
Molecular diagnostic devices
Testing services

Intellectual Property and Licensing Agreements

Overview

Provides patents and technical collaboration to promote new drug development.

Competitiveness

Extensive patent portfolio and international partnerships

Customers

Domestic and international pharmaceutical companies
Research institutions

Products

Patent licenses
Technology transfers
Joint research contracts

Competitive Advantage

Strengths

Financial and technical support from Swiss Roche Group
Biopharma technology strength in oncology
R&D bases expanding domestically and internationally
Diverse product pipeline
Solid financial base and high-profitability structure
Maintaining long-term strategic alliances
Comprehensive prescription pharmaceutical lineup
Advanced molecular targeted drug development capabilities
Stable quality control and production technology
Strong connections with domestic medical institutions
High brand recognition and reliability
Global business expansion capabilities
Research efficiency utilizing digital technologies
Corporate stance emphasizing social responsibility
Agile market responsiveness

Competitive Advantages

High new drug development capabilities through strong technology and R&D collaboration with Roche Group
Domestic top-class market share in cancer treatment drugs
Expertise and product diversity across multiple therapeutic areas
Balancing manufacturing and R&D efficiency with multiple institutes and factories in Japan
Robust competitive edge with abundant patents and intellectual property
Differentiated products via advanced biopharma technology
Sustainable R&D investments enabled by stable financial base
Strong sales force through close cooperation with domestic and international medical institutions
Aiming to increase overseas sales ratio through accelerated global expansion
Active promotion of digital transformation
Fostering innovation culture based on corporate slogan
Efficient production operations through manufacturing subsidiary
Focus on social value creation and sustainability
Future potential through securing innovative drug pipeline
High customer satisfaction and trust in medical settings

Threats

Complication of approval processes due to stricter domestic and international pharmaceutical regulations
Intense competition in the global pharmaceutical market
Revenue decline risk from patent expirations
Rapid technological innovation by emerging biotech ventures
Revenue instability from exchange rate fluctuations
Ongoing pressure to lower drug prices
Demand fluctuations due to global economic uncertainty
Rising raw material and manufacturing costs
Profit pressure from escalating R&D expenses
Supply chain vulnerabilities
Increasing legal and regulatory risks
Risk of reputational damage

Innovations

2024: Chugai Life Science Park Yokohama commences operations

Overview: New research base in Yokohama, Kanagawa Prefecture, began operations in April 2023, strengthening R&D.
Impact: Improved research efficiency and accelerated new drug development

2023: Progress in clinical trials for oral anti-obesity drug candidate

Overview: Receiving recognition as the world's top in clinical development of oral obesity treatment drug.
Impact: Heightened expectations for new market creation

2022: Establishment of new Digital/IT Division

Overview: Dedicated division established to promote digital technology utilization and strengthen DX framework.
Impact: Enhanced data analysis efficiency and development speed

2021: Cessation of Future Medicine Research Institute operations

Overview: Optimized resource allocation by ending operations of the Future Medicine Research Institute.
Impact: Resource reallocation and focus on next-generation drug discovery

2020: Expanded adoption of next-generation antibody drug technology

Overview: Advancing R&D of bispecific antibodies utilizing proprietary technologies.
Impact: Diversified new drug pipeline and enhanced competitiveness

Sustainability

Promoting energy-saving in manufacturing processes to reduce environmental impact
Community coexistence through medical access improvement activities
Strict adherence to social ethics and compliance
Advancing internal diversity and strengthening talent development
Implementing sustainable supply chain management
Setting and reporting CO2 emission reduction targets
Promoting awareness activities for safe use of pharmaceuticals
Promoting environmental protection through waste reduction
CSR activities supporting health and quality of life improvement
Enhancing information disclosure for corporate transparency
Pursuing both new drug development and environmental technologies
Supporting global infectious disease countermeasures